Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors

References

• Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al. Use of CAR-Transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545–15. PMID: 32023374. doi:10.1056/NEJMoa1910607.
   PubMed Web of Science ®Google Scholar
• Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fane A, Gaudernack G, Kvalheim G, Myklebust JH, et al. NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine. 2019;40:106–17. PMID: 30665853. doi:10.1016/j.ebiom.2019.01.031.
   PubMed Web of Science ®Google Scholar
• Morton LT, Wachsmann TLA, Meeuwsen MH, Wouters AK, Remst DFG, van Loenen MM, Falkenburg JHF, Heemskerk MHM, van Loenen MM. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. J ImmunoTher Cancer. 2022;10(3):e003715. PMID: 35288464. doi:10.1136/jitc-2021-003715.
   PubMed Web of Science ®Google Scholar
• Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975. doi:10.1016/j.ebiom.2020.102975. PMID: 32853984.
   PubMed Web of Science ®Google Scholar
• Marofi F, Abdul-Rasheed OF, Rahman HS, Budi HS, Jalil AT, Yumashev AV, Hassanzadeh A, Yazdanifar M, Motavalli R, Chartrand MS, et al. CAR-NK cell in cancer immunotherapy; a promising frontier. Cancer Sci. 2021;112(9):3427–36. PMID: 34050690. doi:10.1111/cas.14993.
   PubMed Web of Science ®Google Scholar
• Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557–75. PMID: 35879429. doi:10.1038/s41568-022-00491-0.
   PubMed Web of Science ®Google Scholar
• Heipertz EL, Zynda ER, Stav-Noraas TE, Hungler AD, Boucher SE, Kaur N, Vemuri MC. Current perspectives on “off-the-shelf” allogeneic NK and CAR-NK cell therapies. Front Immunol. 2021;12:732135. PMID: 34925314. doi:10.3389/fimmu.2021.732135.
   PubMed Web of Science ®Google Scholar
• Pinto S, Pahl J, Schottelius A, Carter PJ, Koch J. Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends Immunol. 2022;43(11):932–46. PMID: 36306739. doi:10.1016/j.it.2022.09.007.
   PubMed Web of Science ®Google Scholar
• Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 2021;12:713158. PMID: 34394116. doi:10.3389/fimmu.2021.713158.
   PubMed Web of Science ®Google Scholar
• Lazarova M, Steinle A. The NKG2D axis: an emerging target in cancer immunotherapy. Expert Opin Ther Targets. 2019;23(4):281–94. PMID: 30732494. doi:10.1080/14728222.2019.1580693.
   PubMed Web of Science ®Google Scholar
• Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2):S3–23. PMID: 20176265. doi:10.1016/j.jaci.2009.12.980.
   PubMed Web of Science ®Google Scholar
• Krzewski K, Coligan JE. Human NK cell lytic granules and regulation of their exocytosis. Front Immunol. 2012;3:335. PMID: 23162553. doi:10.3389/fimmu.2012.00335.
   PubMed Web of Science ®Google Scholar
• Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105(6):1319–29. PMID: 31107565. doi:10.1002/JLB.MR0718-269R.
   PubMed Web of Science ®Google Scholar
• Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495–502. PMID: 18425106. doi:10.1038/ni1581.
   PubMed Web of Science ®Google Scholar
• Hwang JR, Byeon Y, Kim D, Park SG. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Experimental & Molecular Medi. 2020;52(5):750–61. PMID: 32439954. doi:10.1038/s12276-020-0435-8.
   PubMed Web of Science ®Google Scholar
• Courtney AH, Lo WL, Weiss A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem Sci. 2018;43(2):108–23. PMID: 29269020. doi:10.1016/j.tibs.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Purbhoo MA, Irvine DJ, Huppa JB, Davis MM. T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol. 2004;5(5):524–30. PMID: 15048111. doi:10.1038/ni1058.
   PubMed Web of Science ®Google Scholar
• Krovi SH, Gapin L. Invariant natural killer T cell subsets-more than just developmental intermediates. Front Immunol. 2018;9:1393. PMID: 29973936. doi:10.3389/fimmu.2018.01393.
   PubMed Web of Science ®Google Scholar
• Kalyan S, Kabelitz D. Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic. Cell Mol Immunol. 2013;10(1):21–29. PMID: 23085947. doi:10.1038/cmi.2012.44.
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869. PMID: 30150991. doi:10.3389/fimmu.2018.01869.
   PubMed Web of Science ®Google Scholar
• Quatrini L, Della Chiesa M, Sivori S, Mingari MC, Pende D, Moretta L. Human NK cells, their receptors and function. Eur J Immunol. 2021;51(7):1566–79. PMID: 33899224. doi:10.1002/eji.202049028.
   PubMed Web of Science ®Google Scholar
• Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L. Human NK cells: surface receptors, inhibitory checkpoints, and translational applications. Cell Mol Immunol. 2019;16(5):430–41. PMID: 30778167. doi:10.1038/s41423-019-0206-4.
   PubMed Web of Science ®Google Scholar
• Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018;154(3):383–93. PMID: 29512837. doi:10.1111/imm.12921.
   PubMed Web of Science ®Google Scholar
• Debska-Zielkowska J, Moszkowska G, Zielinski M, Zielinska H, Dukat-Mazurek A, Trzonkowski P, Stefanska K. KIR receptors as key regulators of NK cells activity in health and disease. Cells. 2021;10(7):1777. PMID: 34359951. doi:10.3390/cells10071777.
   PubMed Web of Science ®Google Scholar
• Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol. 2019;10:909. PMID: 31134055. doi:10.3389/fimmu.2019.00909.
   PubMed Web of Science ®Google Scholar
• Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4(6):573–81. PMID: 8673704. doi:10.1016/s1074-7613(00)70060-4.
   PubMed Web of Science ®Google Scholar
• Sivori S, Parolini S, Falco M, Marcenaro E, Biassoni R, Bottino C, Moretta L, Moretta A. 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol. 2000;30:787–93. PMID: 10741393. doi:10.1002/1521-4141(200003)30:3<787:AID-IMMU787>3.0.CO;2-I.
   PubMed Web of Science ®Google Scholar
• Vitale M, Falco M, Castriconi R, Parolini S, Zambello R, Semenzato G, Biassoni R, Bottino C, Moretta L, Moretta A. Identification of NKp80, a novel triggering molecule expressed by human NK cells. Eur J Immunol. 2001;31:233–42. PMID: 11265639. doi:10.1002/1521-4141(200101)31:1<233:AID-IMMU233>3.0.CO;2-4.
   PubMed Web of Science ®Google Scholar
• Sivori S, Della Chiesa M, Carlomagno S, Quatrini L, Munari E, Vacca P, Tumino N, Mariotti FR, Mingari MC, Pende D, et al. Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of cancer. Front Immunol. 2020;11:2156. PMID: 33013909. doi:10.3389/fimmu.2020.02156.
   PubMed Web of Science ®Google Scholar
• van Hall T, Andre P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E, van der Burg SH. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J ImmunoTher Cancer. 2019;7(1):263. PMID: 31623687. doi:10.1186/s40425-019-0761-3.
   PubMed Web of Science ®Google Scholar
• Innate P. Safety and efficacy of lacutamab in patients with relapse peripheral T-cell lymphoma that express KIR3DL2Safety and Efficacy of Lacutamab in Patients With Relapse Peripheral T-cell Lymphoma That Express KIR3DL2. 2022. (NCT05321147).
   Google Scholar
• The lymphoma academic research O, Innate P. study of lacutamab in peripheral T-cell lymphoma. Study of Lacutamab in Peripheral T-Cell Lymphoma. 2025. (NCT04984837).
   Google Scholar
• Vey N, Dumas P-Y, Recher C, Gastaud L, Lioure B, Bulabois C-E, Pautas C, Marolleau J-P, Leprêtre S, Raffoux E, et al. Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) as maintenance treatment in elderly Patients (pts) with acute myeloid leukemia (AML): results of the effikir trial. Blood. 2017;130(Suppl_1):889. doi:10.1182/blood.V130.Suppl_1.889.889.
   Google Scholar
• Grivas P, Yin J, Koshkin VS, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, et al. PrE0807: a phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2021;39(15_suppl):4518. doi:10.1200/JCO.2021.39.15_suppl.4518.
   Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–85. PMID: 31676858. doi:10.1038/s41577-019-0224-6.
   PubMed Web of Science ®Google Scholar
• Harjunpaa H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108–19. PMID: 31828774. doi:10.1111/cei.13407.
   PubMed Web of Science ®Google Scholar
• Shao JY, Yin WW, Zhang QF, Liu Q, Peng ML, Hu HD, Hu P, Ren H, Zhang DZ. Siglec-7 Defines a highly functional natural killer cell subset and inhibits cell-mediated activities. Scand J Immunol. 2016;84(3):182–90. PMID: 27312286. doi:10.1111/sji.12455.
   PubMed Web of Science ®Google Scholar
• Lankry D, Simic H, Klieger Y, Levi-Schaffer F, Jonjic S, Mandelboim O. Expression and function of CD300 in NK cells. J Immunol. 2010;185(5):2877–86. PMID: 20656921. doi:10.4049/jimmunol.0903347.
   PubMed Web of Science ®Google Scholar
• Meyaard L, Adema GJ, Chang C, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes. Immunity. 1997;7(2):283–90. PMID: 9285412. doi:10.1016/s1074-7613(00)80530-0.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. PMID: 32433532. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16(1):223–49. PMID: 33197221. doi:10.1146/annurev-pathol-042020-042741.
   PubMed Web of Science ®Google Scholar
• Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–68. PMID: 30198904. doi:10.1172/JCI99317.
   PubMed Web of Science ®Google Scholar
• Hasim MS, Marotel M, Hodgins JJ, Vulpis E, Makinson OJ, Asif S, Shih HY, Scheer AK, MacMillan O, Alonso FG, et al. When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer. Sci Adv. 2022;8(15):eabj3286. PMID: 35417234. doi:10.1126/sciadv.abj3286.
   PubMed Web of Science ®Google Scholar
• Lee H, Quek C, Silva I, Tasker A, Batten M, Rizos H, Lim SY, Nur Gide T, Shang P, Attrill GH, et al. Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. Oncoimmunology. 2019;8(2):e1537581. PMID: 30713793. doi:10.1080/2162402X.2018.1537581.
   PubMed Web of Science ®Google Scholar
• Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6(12):1548–60. PMID: 30282672. doi:10.1158/2326-6066.CIR-18-0062.
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood. 2010;116(13):2286–94. PMID: 20460501. doi:10.1182/blood-2010-02-271874.
   PubMed Web of Science ®Google Scholar
• Trefny MP, Kaiser M, Stanczak MA, Herzig P, Savic S, Wiese M, Lardinois D, Laubli H, Uhlenbrock F, Zippelius A. PD-1(+) natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunol Immunother. 2020;69(8):1505–17. PMID: 32296919. doi:10.1007/s00262-020-02558-z.
   PubMed Web of Science ®Google Scholar
• Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, Zhang J, Benson DM, He K, Caligiuri MA, et al. The mechanism of anti–PD-L1 antibody efficacy against PD-L1–Negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 2019;9(10):1422–37. PMID: 31340937. doi:10.1158/2159-8290.CD-18-1259.
   PubMed Web of Science ®Google Scholar
• Sierra JM, Secchiari F, Nunez SY, Iraolagoitia XLR, Ziblat A, Friedrich AD, Regge MV, Santilli MC, Torres NI, Gantov M, et al. Tumor-Experienced Human NK cells express high levels of PD-L1 and Inhibit CD8(+) T Cell Proliferation. Front Immunol. 2021;12:745939. PMID: 34616407. doi:10.3389/fimmu.2021.745939.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. PMID: 18064051. doi:10.1038/nri2206.
   PubMed Web of Science ®Google Scholar
• Phillips NE, Parker DC. Cross-linking of B lymphocyte Fc gamma receptors and membrane immunoglobulin inhibits anti-immunoglobulin-induced blastogenesis. J Immunol. 1984;132(2):627–32. PMID: 6228594. https://www.ncbi.nlm.nih.gov/pubmed/6228594.
   PubMed Web of Science ®Google Scholar
• Anania JC, Chenoweth AM, Wines BD, Hogarth PM. The human FcgammaRII (CD32) family of leukocyte FcR in health and disease. Front Immunol. 2019;10:464. PMID: 30941127. doi:10.3389/fimmu.2019.00464.
   PubMed Web of Science ®Google Scholar
• Herter S, Birk MC, Klein C, Gerdes C, Umana P, Bacac M. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 2014;192(5):2252–60. PMID: 24489098. doi:10.4049/jimmunol.1301249.
   PubMed Web of Science ®Google Scholar
• Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–33. PMID: 29166586. doi:10.1016/j.immuni.2017.10.008.
   PubMed Web of Science ®Google Scholar
• Hashemi E, Malarkannan S. Tissue-resident NK cells: development, maturation, and clinical relevance. Cancers (Basel). 2020;12(6):1553. PMID: 32545516. doi:10.3390/cancers12061553.
   PubMed Web of Science ®Google Scholar
• Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS, Silva AJD. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol. 2006;43(8):1183–93. PMID: 16102830. doi:10.1016/j.molimm.2005.07.010.
   PubMed Web of Science ®Google Scholar
• Coenon L, Villalba M. From CD16a biology to antibody-dependent cell-mediated cytotoxicity improvement. Front Immunol. 2022;13:913215. PMID: 35720368. doi:10.3389/fimmu.2022.913215.
   PubMed Web of Science ®Google Scholar
• Bruhns P, Jonsson F. Mouse and human FcR effector functions. Immunol Rev. 2015;268(1):25–51. PMID: 26497511. doi:10.1111/imr.12350.
   PubMed Web of Science ®Google Scholar
• Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100(5):1059–70. PMID: 9276722. doi:10.1172/JCI119616.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99(3):754–58. PMID: 11806974. doi:10.1182/blood.v99.3.754.
   PubMed Web of Science ®Google Scholar
• Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-engineering for modulated effector functions—improving antibodies for cancer treatment. Antibodies (Basel). 2020;9(4):64. PMID: 33212886. doi:10.3390/antib9040064.
   PubMedGoogle Scholar
• Pereira NA, Chan KF, Lin PC, Song Z. The “less-is-more” in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs. 2018;10(5):693–711. PMID: 29733746. doi:10.1080/19420862.2018.1466767.
   PubMed Web of Science ®Google Scholar
• Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein & Cell. 2018;9(1):63–73. PMID: 28986820. doi:10.1007/s13238-017-0473-8.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103(11):4005–10. PMID: 16537476. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem. 2001;276(9):6591–604. PMID: 11096108. doi:10.1074/jbc.M009483200.
   PubMed Web of Science ®Google Scholar
• Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res. 2007;67(18):8882–90. PMID: 17875730. doi:10.1158/0008-5472.CAN-07-0696.
   PubMed Web of Science ®Google Scholar
• Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol. 2004;336(5):1239–49. PMID: 15037082. doi:10.1016/j.jmb.2004.01.007.
   PubMed Web of Science ®Google Scholar
• Li C, Li T, Wang LX. Chemoenzymatic defucosylation of therapeutic antibodies for enhanced effector functions using bacterial alpha-fucosidases. Methods Mol Biol. 2018;1827:367–80. PMID: 30196507. doi:10.1007/978-1-4939-8648-4_19.
   PubMedGoogle Scholar
• Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law CL, Sussman D, et al. Development of orally active inhibitors of protein and cellular fucosylation. Proc Natl Acad Sci U S A. 2013;110(14):5404–09. PMID: 23493549. doi:10.1073/pnas.1222263110.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Imai-Nishiya H, Kuni-Kamochi R, Mori K, Inoue M, Kitajima-Miyama K, Okazaki A, Iida S, Shitara K, Satoh M. Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: a new strategy for generating completely non-fucosylated recombinant therapeutics. J Biotechnol. 2007;130(3):300–10. PMID: 17559959. doi:10.1016/j.jbiotec.2007.04.025.
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87(5):614–22. PMID: 15352059. doi:10.1002/bit.20151.
   PubMed Web of Science ®Google Scholar
• Musolino A, Gradishar WJ, Rugo HS, Nordstrom JL, Rock EP, Arnaldez F, Pegram MD. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J ImmunoTher Cancer. 2022;10(1):e003171. PMID: 34992090. doi:10.1136/jitc-2021-003171.
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. MAbs. 2012;4(4):419–25. PMID: 22699226. doi:10.4161/mabs.20996.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305–09. PMID: 24292623. doi:10.1126/science.1244917.
   PubMed Web of Science ®Google Scholar
• Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds. Blood. 2015;126(1):50–60. PMID: 26002964. doi:10.1182/blood-2015-01-625004.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104–15. PMID: 31141632. doi:10.1056/NEJMoa1817249.
   PubMed Web of Science ®Google Scholar
• Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen P, Geissler J, Lissenberg-Thunnissen S, et al. FcγRIIIb restricts antibody-dependent destruction of cancer cells by human neutrophils. Front Immunol. 2018;9:3124. PMID: 30761158. doi:10.3389/fimmu.2018.03124.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024–31. PMID: 25887777. doi:10.1182/blood-2014-12-614636.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, et al. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2020;136(21):2401–09. PMID: 32730586. doi:10.1182/blood.2019004701.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Banerjee P, Kaur I, Bassett R, Kerbauy L, Basar R, Kaplan M, Griffin L, Esqueda D, Ganesh C, et al. Abstract CT003: innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. Cancer Res. 2022;82(12_Supplement):CT003. doi:10.1158/1538-7445.Am2022-ct003.
   Web of Science ®Google Scholar
• Kakiuchi-Kiyota S, Ross T, Wallweber HA, Kiefer JR, Schutten MM, Adedeji AO, Cai H, Hendricks R, Cohen S, Myneni S, et al. A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma. Leukemia. 2022;36(4):1006–14. PMID: 35001074. doi:10.1038/s41375-021-01478-w.
   PubMed Web of Science ®Google Scholar
• Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, et al. Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma. Clin Hematol Int. 2023;5(1):43–51. PMID: 36656461. doi:10.1007/s44228-022-00023-5.
   PubMedGoogle Scholar
• Gt Biopharma I. GTB-3550 tri-specific killer engager (TriKE®) for high risk hematological malignancies. In: GTB-3550 tri-specific killer engager (TriKE®) for high risk hematological malignancies. 2021. (NCT03214666).
   Google Scholar
• Vallera DA, Ferrone S, Kodal B, Hinderlie P, Bendzick L, Ettestad B, Hallstrom C, Zorko NA, Rao A, Fujioka N, et al. NK-Cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo. Cancers (Basel). 2020;12(9):2659. PMID: 32961861. doi:10.3390/cancers12092659.
   PubMed Web of Science ®Google Scholar
• Phung SK, Miller JS, Felices M. Bi-specific and Tri-specific NK Cell engagers: the new avenue of targeted NK cell immunotherapy. Molecular Diagnosis & Therapy. 2021;25(5):577–92. PMID: 34327614. doi:10.1007/s40291-021-00550-6.
   PubMed Web of Science ®Google Scholar
• Demaria O, Gauthier L, Debroas G, Vivier E. Natural killer cell engagers in cancer immunotherapy: next generation of immuno-oncology treatments. Eur J Immunol. 2021;51(8):1934–42. PMID: 34145579. doi:10.1002/eji.202048953.
   PubMed Web of Science ®Google Scholar
• Watkins-Yoon J, Guzman W, Oliphant A, Haserlat S, Leung A, Chottin C, Ophir M, Vekeria J, Nelson AP, Frye Z, et al. CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma. Blood. 2019;134(Supplement_1):3182. doi:10.1182/blood-2019-128749.
   Google Scholar
• Sanofi. First-in-human study of sar443579 infusion in male and female participants of at least 12 years of age with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS). First-In-Human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-Myelodysplasia (HR-MDS). 2024. (NCT05086315).
   Google Scholar
• Demaria O, Habif G, Le Floch F, Chiossone L, Remark R, Vetizou M, Maurel N, Gauthier L, Morel Y, Paturel C, et al. IPH6501 is a Novel NKp46-targeting tetraspecific antibody-based natural killer cell engager therapeutic (ANKET) armed with a non-alpha IL-2 variant and developed for the treatment of CD20-positive malignancies. Blood. 2022;140(Supplement 1):11559. doi:10.1182/blood-2022-163561.
   Google Scholar
• Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428):727–29. PMID: 10426993. doi:10.1126/science.285.5428.727.
   PubMed Web of Science ®Google Scholar
• Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31(1):413–41. PMID: 23298206. doi:10.1146/annurev-immunol-032712-095951.
   PubMed Web of Science ®Google Scholar
• Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology. 2013;2(10):e26097. PMID: 24353908. doi:10.4161/onci.26097.
   PubMed Web of Science ®Google Scholar
• Wensveen FM, Jelencic V, Polic B. NKG2D: a master regulator of immune cell responsiveness. Front Immunol. 2018;9:441. PMID: 29568297. doi:10.3389/fimmu.2018.00441.
   PubMed Web of Science ®Google Scholar
• Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. Nkg2D-DAP10 triggers human NK cell–mediated killing via a Syk-independent regulatory pathway. Nat Immunol. 2003;4(6):557–64. PMID: 12740575. doi:10.1038/ni929.
   PubMed Web of Science ®Google Scholar
• Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Kessler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, et al. The bispecific immunoligand ULBP2-Acea redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma. Int J Cancer. 2014;134(12):2829–40. PMID: 24242212. doi:10.1002/ijc.28609.
   PubMed Web of Science ®Google Scholar
• Kellner C, Hallack D, Glorius P, Staudinger M, Mohseni Nodehi S, de Weers M, van de Winkel JG, Parren PW, Stauch M, Valerius T, et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia. 2012;26(4):830–34. PMID: 22005785. doi:10.1038/leu.2011.288.
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol. 2001;2(3):255–60. PMID: 11224526. doi:10.1038/85321.
   PubMed Web of Science ®Google Scholar
• Spies T. Regulation of NKG2D ligands: a purposeful but delicate affair. Nat Immunol. 2008;9(9):1013–15. PMID: 18711442. doi:10.1038/ni0908-1013.
   PubMed Web of Science ®Google Scholar
• McFarland BJ, Strong RK. Thermodynamic analysis of degenerate recognition by the NKG2D immunoreceptor: not induced fit but rigid adaptation. Immunity. 2003;19(6):803–12. PMID: 14670298. doi:10.1016/s1074-7613(03)00320-0.
   PubMed Web of Science ®Google Scholar
• Li P, Morris DL, Willcox BE, Steinle A, Spies T, Strong RK. Complex structure of the activating immunoreceptor NKG2D and its MHC class I–like ligand MICA. Nat Immunol. 2001;2(5):443–51. PMID: 11323699. doi:10.1038/87757.
   PubMed Web of Science ®Google Scholar
• Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, Stevanovic S, Rammensee HG, Steinle A. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68(15):6368–76. PMID: 18676862. doi:10.1158/0008-5472.CAN-07-6768.
   PubMed Web of Science ®Google Scholar
• Liu G, Atteridge CL, Wang X, Lundgren AD, Wu JD. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule a independent of a disintegrin and metalloproteinases. J Immunol. 2010;184(7):3346–50. PMID: 20208009. doi:10.4049/jimmunol.0903789.
   PubMed Web of Science ®Google Scholar
• Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78(2):120–29. PMID: 23679194. doi:10.1111/sji.12072.
   PubMed Web of Science ®Google Scholar
• Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V, Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007;447(7143):482–86. PMID: 17495932. doi:10.1038/nature05768.
   PubMed Web of Science ®Google Scholar
• Salih HR, Rammensee HG, Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002;169(8):4098–102. PMID: 12370336. doi:10.4049/jimmunol.169.8.4098.
   PubMed Web of Science ®Google Scholar
• Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734–38. PMID: 12384702. doi:10.1038/nature01112.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Chen N, Yu Y, Zhou L, Niu C, Liu Y, Tian H, Lv Z, Han F, Cui J. Prognostic value of MICA/B in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96384–95. PMID: 29221214. doi:10.18632/oncotarget.21466.
   PubMedGoogle Scholar
• Fang L, Gong J, Wang Y, Liu R, Li Z, Wang Z, Zhang Y, Zhang C, Song C, Yang A, et al. MICA/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma. J Exp Clin Cancer Res. 2014;33(1):76. PMID: 25228093. doi:10.1186/s13046-014-0076-7.
   PubMedGoogle Scholar
• Klussmeier A, Massalski C, Putke K, Schafer G, Sauter J, Schefzyk D, Pruschke J, Hofmann J, Furst D, Carapito R, et al. High-throughput MICA/B genotyping of over two million samples: workflow and allele frequencies. Front Immunol. 2020;11:314. PMID: 32153595. doi:10.3389/fimmu.2020.00314.
   PubMed Web of Science ®Google Scholar
• Zelkovic S Celyad oncology provides strategic update., Celyad oncology provides strategic update. Company Website: Celyad Oncology. 2022
   Google Scholar
• Zelkovic S. Celyad oncology provides updates on allogeneic and autologous CAR T programs at 62nd ASH annual meeting and exposition. In: Celyad oncology. Celyad oncology provides updates on allogeneic and autologous CAR T programs at 62nd ASH annual meeting and exposition. Belgium: Mont-Saint-Guibert; 2020. p. 4.
   Google Scholar
• Sallman DA, Kerre T, Havelange V, Poire X, Lewalle P, Wang ES, Brayer JB, Davila ML, Moors I, Machiels JP, et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 2023;10(3):e191–202. PMID: 36764323. doi:10.1016/S2352-3026(22)00378-7.
   PubMed Web of Science ®Google Scholar
• Celyad Oncology SA. Study in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome patients to determine the recommended dose of CYAD-02. In: Study in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome patients to determine the recommended dose of CYAD-02. 2021. (NCT04167696).
   Google Scholar
• Deeren D, Maertens JA, Lin TL, Beguin Y, Alcantar-Orozco E, Dheur M-S, Breman E, Braun N, Lonez C, Gilham D, et al. Co-expression of an shRNA targeting MICA/Micb improves the clinical activity of a NKG2D-Based CAR T in patients with relapsed/refractory AML/MDS. Blood. 2021;138(Supplement 1):408. doi:10.1182/blood-2021-152413.
   Google Scholar
• Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14–32. PMID: 11133738. doi:10.1182/blood.v97.1.14.
   PubMed Web of Science ®Google Scholar
• Nkarta I. NKX101, intravenous allogeneic CAR NK cells, in adults with AML or MDSNKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS. 2023. (NCT04623944).
   Google Scholar
• Mann G. Nkarta announces positive preliminary dose finding data for two lead engineered natural killer cell programs. In: Nkarta announces positive preliminary dose finding data for two lead engineered natural killer cell programs. Company website; 2022.
   Google Scholar
• Curio S, Jonsson G, Marinovic S. A summary of current NKG2D-based CAR clinical trials. Immunother Adv. 2021;1(1):ltab018. PMID: 34604863. doi:10.1093/immadv/ltab018.
   PubMedGoogle Scholar
• Goulding J, Hancock B, Blum R, Yeh W-I, Chang C-W, Pribadi M, Pan Y, Chu H-Y, Sikaroodi S, Dailey T, et al. 204 combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity. J ImmunoTher Cancer. 2022;10:A217. doi:10.1136/jitc-2022-SITC2022.0204.
   Web of Science ®Google Scholar
• Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, Hancock B, Mahmood S, Abujarour R, Wang H, et al. Harnessing features of adaptive NK cells to generate Ipsc-derived NK cells for enhanced immunotherapy. Cell Stem Cell. 2021;28(12):2062–75 e2065. PMID: 34525347. doi:10.1016/j.stem.2021.08.013.
   PubMed Web of Science ®Google Scholar
• Tartaglia C. Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives. In: Fate therapeutics announces termination of collaboration agreement with janssen, pipeline prioritization, next-generation programs, and key 2023 initiatives. Fate Therapeutics Company Website; 2023.
   Google Scholar
• Hagelstein I, Lutz MS, Schmidt M, Heitmann JS, Malenke E, Zhou Y, Clar KL, Kopp HG, Jung G, Salih HR, et al. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins as novel treatment option in advanced soft tissue sarcomas. Front Immunol. 2021;12:653081. PMID: 33936075. doi:10.3389/fimmu.2021.653081.
   PubMed Web of Science ®Google Scholar
• Acheampong DO, Tang M, Wang Y, Zhao X, Xie W, Chen Z, Tian W, Wang M, Zhang J. A novel fusion antibody exhibits antiangiogenic activity and stimulates NK cell-mediated immune surveillance through fused NKG2D ligand. J Immunother (1991). 2017;40(3):94–103. PMID: 28234666. doi:10.1097/CJI.0000000000000157.
   Web of Science ®Google Scholar
• Wang Y, Li H, Xu W, Pan M, Qiao C, Cai J, Xu J, Wang M, Zhang J. BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma. J Immunother (1991). 2020;43(6):175–88. PMID: 32349046. doi:10.1097/CJI.0000000000000320.
   Web of Science ®Google Scholar
• Wang T, Sun F, Xie W, Tang M, He H, Jia X, Tian X, Wang M, Zhang J. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Cancer Lett. 2016;372(2):166–78. PMID: 26791237. doi:10.1016/j.canlet.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Bykova K, Faber M, Liu K, Siddiqi N, Bernett M, Bonzon C, Diaz J, Nam DH, Avery K, Qi J, et al. 787 Natural killer cell engagers activate innate and adaptive immunity and show synergy with proinflammatory cytokines. J ImmunoTher Cancer. 2021;9(Suppl 2):A822. doi:10.1136/jitc-2021-SITC2021.787.
   Google Scholar
• Du C, Bevers J 3rd, Cook R, Lombana TN, Rajasekaran K, Matsumoto M, Spiess C, Kim JM, Ye Z. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner. J ImmunoTher Cancer. 2019;7(1):207. PMID: 31387641. doi:10.1186/s40425-019-0687-9.
   PubMed Web of Science ®Google Scholar
• Arreygue-Garcia NA, Daneri-Navarro A, Del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, et al. Augmented serum level of major histocompatibility complex class I-related chain a (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions. BMC Cancer. 2008;8(1):16. PMID: 18208618. doi:10.1186/1471-2407-8-16.
   PubMedGoogle Scholar
• Kloss S, Chambron N, Gardlowski T, Arseniev L, Koch J, Esser R, Glienke W, Seitz O, Kohl U. Increased sMICA and TGFβ 1 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology. 2015;4(11):e1055993. PMID: 26451327. doi:10.1080/2162402X.2015.1055993.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain a in advanced human hepatocellular carcinomas. J Hepatol. 2005;43(6):1013–20. PMID: 16168521. doi:10.1016/j.jhep.2005.05.026.
   PubMed Web of Science ®Google Scholar
• Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, Ji Z, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020;13(1):74. PMID: 32517713. doi:10.1186/s13045-020-00896-0.
   PubMed Web of Science ®Google Scholar
• Zhang J, Larrocha PS, Zhang B, Wainwright D, Dhar P, Wu JD. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1/PD-L1 blockade therapy. J ImmunoTher Cancer. 2019;7(1):223. PMID: 31446896. doi:10.1186/s40425-019-0693-y.
   PubMed Web of Science ®Google Scholar
• Lu S, Zhang J, Liu D, Li G, Staveley-O’Carroll KF, Li Z, Wu JD. Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors. Clin Cancer Res. 2015;21(21):4819–30. PMID: 26106076. doi:10.1158/1078-0432.CCR-15-0845.
   PubMed Web of Science ®Google Scholar
• Blery M, Mrabet-Kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, Gauthier L, Rossi B, Remark R, Cornen S, et al. Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control [version 2; peer review: 2 approved]. Open Res Eur. 2021;1:107. PMID: 35967081. doi:10.12688/openreseurope.13314.2.
   PubMedGoogle Scholar
• Ferrari de Andrade L, Kumar S, Luoma AM, Ito Y, da Silva PH A, Pan D, Pyrdol JW, Yoon CH, Wucherpfennig KW. Inhibition of MICA and MICB shedding elicits NK-Cell–Mediated immunity against tumors resistant to cytotoxic T cells. Cancer Immunol Res. 2020;8(6):769–80. PMID: 32209637. doi:10.1158/2326-6066.CIR-19-0483.
   PubMed Web of Science ®Google Scholar
• de Andrade L F, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF HC Jr., Harvey CJ, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity. Science. 2018;359(6383):1537–42. PMID: 29599246. doi:10.1126/science.aao0505.
   PubMed Web of Science ®Google Scholar
• Badrinath S, Dellacherie MO, Li A, Zheng S, Zhang X, Sobral M, Pyrdol JW, Smith KL, Lu Y, Haag S, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606(7916):992–98. PMID: 35614223. doi:10.1038/s41586-022-04772-4.
   PubMed Web of Science ®Google Scholar
• Whalen K, Naveen M, Meetze K, Gibson N, Michaelson J, Baeuerle P. 1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity. J ImmunoTher Cancer. 2022;10:A1450. doi:10.1136/jitc-2022-SITC2022.1395.
   Web of Science ®Google Scholar
• Whalen KA, Mehta NK, Yalcin S, Meetze K, Gibson NW, Michaelson JS, Baeuerle PA. Abstract 3506: cLN-619, a clinical-stage MICA/MICB-specific IgG1 antibody, restores the MICA/MICB-NKG2D axis to promote NK-mediated tumor cell lysis. Cancer Res. 2022;82(12_Supplement):3506. doi:10.1158/1538-7445.Am2022-3506.
   Web of Science ®Google Scholar
• Parsons MS, Richard J, Lee WS, Vanderven H, Grant MD, Finzi A, Kent SJ. NKG2D acts as a co-receptor for natural killer cell-mediated anti-HIV-1 antibody-dependent cellular cytotoxicity. AIDS Res Hum Retroviruses. 2016;32(10–11):1089–96. PMID: 27487965. doi:10.1089/AID.2016.0099.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol. 2019;10:3038. PMID: 32038612. doi:10.3389/fimmu.2019.03038.
   PubMed Web of Science ®Google Scholar
• Habif G, Crinier A, Andre P, Vivier E, Narni-Mancinelli E. Targeting natural killer cells in solid tumors. Cell Mol Immunol. 2019;16(5):415–22. PMID: 30911118. doi:10.1038/s41423-019-0224-2.
   PubMed Web of Science ®Google Scholar
• Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, Wang Y, Xiong F, Guo C, Li Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18(1):29. PMID: 30813924. doi:10.1186/s12943-019-0956-8.
   PubMedGoogle Scholar